Most Recent Articles about INCY
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I http://www.zacks.com/stock/news/429331/concert-pharmas-ctp-692-positive-for-schizophrenia-in-phase-i?cid=CS-ZC-FT-429331 Jun 13, 2019 - Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/428338/mercks-keytruda-wins-fda-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-428338 Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Incyte Begins Phase III Study for Treatment of Duct Cancer http://www.zacks.com/stock/news/425849/incyte-begins-phase-iii-study-for-treatment-of-duct-cancer?cid=CS-ZC-FT-425849 Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.

Related Companies

Name Exchange Price Mkt Cap
EXAS Exact Sciences Corporation NASDAQ $73.32 $9B
ICLR ICON plc NASDAQ $145.39 $7.9B
PRAH PRA Health Sciences, Inc. NASDAQ $108.16 $6.96B
CRL Charles River Laboratories International, Inc. NYSE $129.19 $6.21B
SYNH Syneos Health, Inc. NASDAQ $47.15 $4.85B
Sector: Health Care > Industry: Biotechnology: Commercial Physical & Biological Resarch